Good Morning Market Enthusiasts,
 

Have you pulled up NanoViricides, Inc. (NYSE American: NNVC) yet???

They just dropped some huge news!  

NanoViricides, Inc. (NYSE American: NNVC) has just signed a groundbreaking agreement with TheraCour Pharma that positions them at the forefront of antiviral drug development. With the right of first refusal on all future antiviral treatments, NanoViricides now holds a key advantage in rapidly developing cutting-edge drugs to combat current and future viral threats. (8)
 

Their lead candidate, NV-387, has already shown incredible results, surpassing existing treatments for a wide range of viruses. With this new agreement, NanoViricides is set to expand its portfolio, including revolutionary “Trojan Horse” drugs that could cure even the most challenging infections. (8)

(2)

Why NanoViricides Stands Out
 

NanoViricides, Inc. is leading the charge in nano-biopharmaceuticals, specializing in discovering, developing, and commercializing therapies to combat the world’s toughest viral infections, including C0\/lD-19 and MPOX. (2)(4)(6)
 

✨ 350% Upside Potential: Analysts predict significant room for growth, with a price target of $6.50. NNVC has been outpacing the S&P 500 for over a year, proving its resilience and potential.

(2)

🔬 Innovative Products: Their lead candidate, NV-387, is in Phase 1 clinical trials targeting C0\/lD-19 and other severe viral infections. Their broad-spectrum antiviral portfolio includes oral solutions and syrups designed to treat severe cases and pediatric needs. (2)(4)(6)
 

🏆 Industry-Leading Leadership: Guided by a visionary team, NanoViricides is strategically positioned for breakthroughs in nanomedicine, making strides while maintaining strong financial discipline. (2)(4)(6)
 

💪 Robust Financials: NanoViricides has consistently exceeded earnings expectations, backed by a strong YTD return. Their financial strength sets the stage for sustained growth. (2)(4)(6)
 

🌟 Latest Achievements: NV-387 has shown sustained antiviral effects with infrequent dosing, a significant advancement in treating viral infections. (2)(4)(6)
 

📊 Strong Technicals: With positive technical indicators, NNVC is poised for a potential breakout. (7)

(7)

🏎️ Consistent Outperformance: NanoViricides has consistently beaten earnings estimates for over a year, reflecting strong financial management and growth potential. (2)

(2) 

Tackling the Global MPOX Threat
 

In addition to their C0\/lD-19 work, NanoViricides is researching the use of NV-387 for the treatment of MPOX under the WHO’s MEURI protocol. As MPOX re-emerges as a global threat, NV-387’s success in preclinical studies shows promise. It has proven as effective as tecovirimat (the current standard treatment) in increasing survival rates in animal studies.

Recent reports highlight the rapid spread of MPOX Clade 1/1b, which has proven more transmissible and severe than previous strains. With few effective treatments available, NV-387 could be a vital tool in combating this public health emergency. (2)(4)(6)
 

Looking Ahead
 

NanoViricides, Inc. (NYSE American: NNVC) isn’t just another biopharma company—they are innovators. By leveraging cutting-edge nanotechnology, they are developing a robust pipeline that addresses some of the world’s most challenging viral threats. Their broad-spectrum antiviral approach has the potential to revolutionize the way we treat viral infections, much like penicillin did for bacterial infections.
 

Stay tuned for more updates as NanoViricides continues to push the boundaries of biopharmaceutical innovation. With a strong leadership team, innovative products, and the potential for 350% upside, now could be the perfect time to add NNVC to your portfolio.
 

To Your Success,

Max Masters

Co-founder, Market Tips Newsletter

Sources:
1. https://on.mktw.net/4ejFQLg
2. https://finance.yahoo.com/quote/NNVC/

3. https://www.nanoviricides.com/

4. https://www.nanoviricides.com/files/News%20PDFs/2024-09-18%20NanoViricides%20Presentation%20-%20with%20Markets.pdf

5. https://finance.yahoo.com/news/sustained-slow-declining-blood-concentration-103000058.html

6. https://finance.yahoo.com/news/nanoviricides-filed-quarterly-report-103000942.html

7. bit.ly/3VPJfLb

8. https://finance.yahoo.com/news/nanoviricides-executes-agreement-encompassing-antiviral-103000370.html

Data is provided from third-party sources and Market Tips is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized fin.ancial advice, are not finan.cial advisors, and our opinions are not suitable for all in.vest.ors. Please review our full disc.laim.er here. 

Pursuant to an agreement between Momentum Media LLC and Interactive Offers LLC, Momentum Media LLC has been hired for a period beginning on 09/25/2024 and ending on 09/26/2024 to publicly disseminate information about (NNVC:US) via digital communications. We have been paid an additional twenty five thousand dollars USD. To date we have been paid fifty eight thousand dollars USD. We own zero shares of (NNVC:US).